Browse Technologies

Displaying 1 - 3 of 3


Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Cameron Sargent

615.322.5907

Anti-inflammatory microparticles for sustained ocular drug delivery

Vanderbilt researchers have developed an injectable drug delivery vehicle using microparticles (MPs) that not only provide sustained cargo delivery over extended time but also play a therapeutic role themselves in reducing inflammation. This drug delivery platform can be used in treating ocular diseases such as glaucoma and traumatic optic neuropathy, as well as other inflammatory diseases throughout the body like peripheral arterial disease and osteoarthritis.


Licensing Contact

Taylor Jordan

615.936.7505

Use of Fluid Shear Stress Treatment to Enhance T Cell Activation

Researchers at Vanderbilt University have developed a technique to enhance immune cell activation by exposing cells to mechanical force while culturing. Proof-of-concept data indicate that activating immune cells with this method may improve therapeutic efficacy and reduce manufacturing expenses, making powerful CAR T cell therapies more accessible to patients in need.


Licensing Contact

Cameron Sargent

615.322.5907